Clenbuterol to Target DUX4 in FSHD (NCT06721299)
Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Who can join: Review the eligibility criteria below.
Location: University of Kansas Medical Center — Kansas City, Kansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Kansas Medical Center — Kansas City, Kansas
- University of Rochester Medical Center — Rochester, New York
- University of Washington — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (913) 945-9936
Email: rclay@kumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscular Dystrophy, Facioscapulohumeral
- Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 — Liverpool, New South Wales
- Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) — Palo Alto, California
Explore by condition: All Muscular Dystrophy, Facioscapulohumeral clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.